Stereotactic Radiotherapy Reduces Prostate Cancer Treatment to Five Sessions

Patients undergoing radiotherapy for localized prostate cancer can now receive treatment in five sessions rather than the traditional 20, following updated clinical practice guidelines. This shift toward Stereotactic Ablative Radiotherapy (SABR)—also known as Stereotactic Body Radiotherapy (SBRT)—delivers high doses of radiation with sub-millimeter precision, significantly reducing the overall duration of care while maintaining efficacy comparable to longer courses. According to National Institute for Health and Care Excellence (NICE) guidelines, this ultra-hypofractionated approach is becoming the standard for eligible patients, offering a more convenient alternative to conventional fractionated radiotherapy.

How Does SABR Differ from Conventional Radiotherapy?

Conventional external beam radiotherapy typically requires patients to attend hospital appointments daily for four to eight weeks. This extended schedule is necessary to allow healthy tissue to recover between lower-dose fractions. In contrast, SABR uses advanced image-guidance technology to target the tumor with extreme accuracy, allowing clinicians to administer a much higher dose per session. By delivering these concentrated doses over just five sessions, the total treatment time is condensed from weeks into roughly one or two weeks. Research published in The Lancet Oncology indicates that this method is non-inferior to conventional schedules for biochemical disease control in localized prostate cancer.

Who Is Eligible for Five-Session Treatment?

Not every prostate cancer diagnosis is suitable for the five-session protocol. Clinical teams evaluate patients based on the stage, grade, and size of the tumor, as well as the anatomy of the surrounding organs at risk, such as the bladder and rectum. According to the Prostate Cancer UK guidance, suitability often depends on whether the cancer is localized (contained within the prostate) and the patient’s specific risk profile. Patients with larger prostate volumes or significant pre-existing urinary symptoms may not be candidates for this specific technique, as the high-dose radiation could increase the risk of side effects in adjacent healthy tissues.

What Are the Benefits and Risks?

The primary advantage of the five-session schedule is the reduction in hospital visits, which improves patient quality of life and lowers the logistical burden on oncology departments. However, because each dose is significantly higher than those used in standard radiotherapy, the precision of the delivery is critical.

• Efficiency: Fewer trips to the hospital mean less time away from work and daily activities.
• Precision: Real-time image guidance ensures the radiation beams remain focused on the target even if the prostate moves slightly.
• Side Effects: Short-term side effects, such as urinary frequency or bowel irritation, may be more intense immediately following treatment compared to lower-dose daily therapy.

Long-term data from studies like the PACE-B trial suggest that side effects remain manageable and are comparable to standard treatments five years post-therapy.

What Happens Next for Prostate Cancer Care?

The widespread adoption of SABR represents a broader trend in oncology toward “hypofractionation,” the practice of delivering radiation in fewer, larger doses. As technology continues to improve, the focus for researchers is on refining the software that accounts for internal organ motion. For patients, the transition to a five-session model means that radiotherapy for prostate cancer is becoming a less disruptive medical intervention. Those interested in this treatment should consult their urologist or clinical oncologist to discuss whether their specific tumor characteristics align with the requirements for ultra-hypofractionated radiotherapy.

Key Takeaways

• Treatment Duration: Standard radiotherapy is being replaced by five-session SABR for many localized prostate cancer cases.
• Evidence Base: Major clinical trials, including PACE-B, have confirmed that high-dose, short-course radiotherapy is as effective as traditional long-course methods.
• Patient Care: The shorter schedule reduces hospital visits but requires precise patient selection to minimize side effects.